Keyphrases
Efficacy Outcomes
100%
Relapsed or Refractory multiple Myeloma
100%
Carfilzomib
100%
Overall Response Rate
33%
Phase II Trial
33%
Specific Response
33%
Baseline Covariates
33%
Response Status
33%
Multiple Myeloma Patients
33%
Confidence Interval
16%
Patient Data
16%
Odds Ratio
16%
Progression-free Survival
16%
Overall Survival
16%
U.S. Food
16%
Logistic Regression Model
16%
Generalized Estimating Equations
16%
Starting Dose
16%
Dose-response Relationship
16%
Duration of Response
16%
Response Time
16%
Previous Treatment
16%
Intention-to-treat
16%
Cox Regression Model
16%
Time to Progression
16%
Target Dose
16%
Time-to-event Outcomes
16%
Medicine and Dentistry
Multiple Myeloma
100%
Carfilzomib
100%
Phase II Trials
33%
Patient-Data
16%
Progression Free Survival
16%
Overall Survival
16%
Proportional Hazards Model
16%
Logistic Regression Analysis
16%
Dose Response
16%
Intention-to-Treat Analysis
16%
Post-Hoc Analysis
16%
Odds Ratio
16%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
100%
Carfilzomib
100%
Phase II Trials
33%
Progression Free Survival
16%
Overall Survival
16%
Dose-Response Relationship
16%